메타게노믹스 시장은 예측기간 중 6.5%의 CAGR을 기록할 것으로 예상됩니다. 연구개발비 증가, 시퀀싱 비용 감소, 기술 진보 등이 시장을 견인하고 있습니다. 또한 메타트랜스크립토믹스, 메타볼로믹스, 메타프로테오믹스에 대한 관심 상승 등도 시장 성장을 촉진하고 있습니다. 또한 DNA 시퀀싱은 메타게노믹스와 강하게 관계되어 있기 때문에 DNA 시퀀싱 분야의 기술 진보는 메타게노믹스 시장에 유리한 기회를 창출합니다. 또한 바이러스성 설사나 인플루엔자, B형 간염, HIV/AIDS 등의 바이러스성 질환과 관련된 우려 고조, 유전자 특정의 진행이 시장을 견인하고 있습니다. 그러나 높은 비용은 시장 성장을 저해할 가능성이 있습니다.
메타게노믹스 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 제품별·기술별·용도별·지역별 시장 규모 추정과 예측, 경쟁 상황, 주요 기업 개요, 시장 기회 등의 정보를 제공합니다.
The Metagenomics Market is expected to register a CAGR of 6.5% during the forecast period. This is attributing to increasing R&D expenditure, declining expenses of sequencing, and technological advancements. In addition, the growing interest of researchers in the field of metatranscriptomics, metabolomics, and metaproteomic and investment in bioinformatics to promote metagenomics and microbiome profiling is also some of the factors propelling the growth of the market. Moreover, As DNA sequencing is highly associated with metagenomics so technological advancement in the field of DNA sequencing results in several advantages compared to conventional methods. Some of the advantages are accuracy, reducing the number of presequencing, and attaining authenticity of the sequencing. These advancements in DNA sequencing will create a lucrative opportunity for the metagenomics market. Furthermore, rising concerns related to viral diseases such as virus-induced diarrhea, influenza, hepatitis B, HIV/AIDS, and a growing number of genes identified leading to promote the development of novel metagenome study products and drive the market. However, the high cost of overall metagenomics may hamper the market to a certain extent.
Metagenomics in the Environmental is Estimated to Witness a Healthy Growth in Future.
Metagenomics in the environment is estimated to witness healthy growth in the future attributed to advancement in the field of genetic study, high demand among researchers to study microbial ecology, and high adoption in several environmental applications such as crop growth, biofuel production, bioremediation through wastewater treatment and gasoline leaks. Moreover, the growing interest of microbiologists in microbes and the ability of Metagenomics to screen uncultured microbes also promoting the segment growth.
In addition, Metagenomics in human health is also anticipated to show significant growth in the forecasted period due to growing demand among researchers to study the relation between microbes and human diseases. The European Project MetaHIT (metagenomics of human intestinal tract) and the American Human Microbiome Project are some of the research programs working in the field of metagenomics. Moreover, rising investment in the human microbiome and introduction of advanced sequencing technologies leading to drive the metagenomics market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global Metagenomics Market due to presence of a large number of pharmaceutical companies focusing on the development of metagenomic workflows, growing research and development expenditure, wide adoption of metagenomics diagnostic, an increasing number of next-generation sequencing (NGS) based research and technological advancements. The United States owns the largest share of the Metagenomics market in the North America region Furthermore, the rapid adoption of novel sequencing technologies and rising awareness about Next Generation Sequencing (NGS) based on metagenomic research is also expected to fuel the Metagenomics Market in this region.
The Metagenomics Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Illumina, Inc., QIAGEN, Novogene Co., Ltd., PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Promega Connections, Bio-Rad Laboratories, Inc., and Merck KGaA.